a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need.
Industry Biotechnology
A.I.dvisor tells us that ONCT and KURA have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ONCT and KURA's prices will move in lockstep.
| Ticker / NAME | Correlation To ONCT | 1D Price Change % | ||
|---|---|---|---|---|
| ONCT | 100% | -0.51% | ||
| KURA - ONCT | 26% Poorly correlated | -4.04% | ||
| HOOK - ONCT | 26% Poorly correlated | -2.49% | ||
| RLMD - ONCT | 25% Poorly correlated | -2.14% | ||
| AFMD - ONCT | 24% Poorly correlated | -6.62% | ||
| EVAX - ONCT | 23% Poorly correlated | +3.61% | ||
More | ||||